Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | PKM | P14618 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | MMP2 | P08253 | 3/20 | 0.50 |
| ▸ | ANPEP | P15144 | 3/20 | 0.50 |
| ▸ | CXCR6 | O00574 | 1/20 | 0.49 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31432699 | 0.85 | MAPK1 (0.74) | MAPK1OPRK1MEN1KMT2APKM | |
| SCHEMBL463415 | 0.85 | MAPK1 (0.74) | MAPK1OPRK1MEN1KMT2APKM | |
| SCHEMBL13845998 | 0.84 | MAPK1 (0.72) | MAPK1OPRK1MEN1KMT2A | |
| SCHEMBL13846013 | 0.84 | MAPK1 (0.72) | MAPK1OPRK1MEN1KMT2A | |
| SCHEMBL3140700 | 0.83 | POLB (0.77) | MAPK1OPRK1MEN1KMT2APKM | |
| SCHEMBL10692729 | 0.81 | MAPK1 (0.68) | MAPK1OPRK1MEN1KMT2A | |
| SCHEMBL9205578 | 0.81 | MAPK1 (0.68) | MAPK1OPRK1MEN1KMT2APKM | |
| SCHEMBL16789648 | 0.80 | MAPK1 (0.67) | MAPK1OPRK1MEN1KMT2APKM | |
| SCHEMBL28324081 | 0.80 | MAPK1 (0.67) | MAPK1OPRK1MEN1KMT2APKM | |
| SCHEMBL14748332 | 0.80 | MAPK1 (0.66) | MAPK1OPRK1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1281 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250259704-A1 | SYSTEMS AND METHODS FOR CELL-FREE ITERATIVE SITE SATURATION MUTAGENESIS AND ITS APPLICATION FOR THE DIRECTED EVOLUTION OF ENZYMES CATALYZING UNNATURAL REACTIONS | U.S. DEPARTMENT OF ENERGY | 2025-08-14 | — | — | US | claimed |
| US-20250129016-A1 | PHOTOREDOX METHODS FOR RADIOCYANATION OF ARENES AND USE THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2025-04-24 | — | — | US | claimed |
| CN-119331762-A | Bifidobacterium breve BX-18 and application thereof | 内蒙古农业大学 | 2025-01-21 | — | — | CN | claimed |
| CN-119233997-A | Tetrahedral antibodies | 生物分子控股有限责任公司 | 2024-12-31 | — | — | CN | claimed |
| EP-4463485-A2 | TETRAHEDRAL ANTIBODIES | Biomolecular Holdings LLC (US) | 2024-11-20 | — | — | EP | claimed |
| CN-118384290-A | Hybrid immunoglobulins containing non-peptide linkages | 生物分子控股有限责任公司 | 2024-07-26 | — | — | CN | claimed |
| EP-4031948-B1 | A METHOD AND A DEVICE FOR PICKING AND PLACING ITEMS | ABB SCHWEIZ AG (CH) | 2024-07-03 | — | — | EP | claimed |
| WO-2023250524-A1 | SYSTEMS AND METHODS FOR CELL-FREE ITERATIVE SITE SATURATION MUTAGENESIS AND ITS APPLICATION FOR THE DIRECTED EVOLUTION OF ENZYMES CATALYZING UNNATURAL REACTIONS | NORTHWESTERN UNIVERSITY (US) | 2023-12-28 | — | — | WO | claimed |
| WO-2023137387-A2 | TETRAHEDRAL ANTIBODIES | BIOMOLECULAR HOLDINGS LLC (US) | 2023-07-20 | — | — | WO | claimed |
| WO-2023137373-A1 | TETRAHEDRAL ANTIBODIES | BIOMOLECULAR HOLDINGS LLC (US) | 2023-07-20 | — | — | WO | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| US-5908824-A | DISPERSED HOMOGENEOUSLY IN AND ADSORBED HOMOGENEOUSLY ONTO A MUCOSA PROTECTING AND/OR TISSUE REPAIRING AGENT | DOTT RESEARCH LABORATORY (JP) | 1999-06-01 | — | — | US | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| CN-2269254-Y | Jet core box for radiator sand core | TAIYUAN SCIENT AND EDUCATION C (CN) | 1997-12-03 | — | — | CN | claimed |
| EP-0770390-A1 | Nasally administrable compositions containing physiologically active peptides | DOTT RESEARCH LABORATORY (JP) | 1997-05-02 | — | — | EP | claimed |
| CN-2234834-Y | Rotary coring type core shooter | TAIYUAN SCIENCE & EDUCATION CO (CN) | 1996-09-11 | — | — | CN | claimed |
| US-5238946-A | Therapeutic agent for gastritis | KYORIN SEIYAKU KABUSHIKI KAISHA (JP) | 1993-08-24 | — | — | US | claimed |
| CN-1069808-A | Determine the method and apparatus of object height | — | 1993-03-10 | — | — | CN | claimed |
| EP-0254068-B1 | NOVEL THERAPEUTIC AGENT FOR GASTRITIS | KYORIN SEIYAKU KABUSHIKI KAISHA (JP) | 1992-08-26 | — | — | EP | claimed |
| EP-0254068-A2 | Novel therapeutic agent for gastritis | KYORIN SEIYAKU KABUSHIKI KAISHA (JP) | 1988-01-27 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129016-A1 | PHOTOREDOX METHODS FOR RADIOCYANATION OF ARENES AND USE THEREOF | RCC2, PPOX, FTO | MAPK1 2762/4885OPRK1 2540/4885MEN1 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.